US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
The American arm of the independent Swiss biotech company Octapharma has appointed Richard Walters as its new vice president of commercial development. 5 June 2017
David Stamler has joined Australia’s Prana Biotechnology as chief medical officer and senior vice president, clinical development, based in San Francisco. 5 June 2017
Privately-held Swiss firm Ferring Pharmaceuticals today announced that Paul Navarre has been appointed chief executive of Ferring Holding Inc. 2 June 2017
Silence Therapeutics has recruited Torsten Hoffmann as chief operating officer, reporting directly to Ali Mortazavi, chief executive. This is not a plc board appointment. 1 June 2017
A cloud is hanging over UK-registered biotech Akari Therapeutics after inaccuracies came to light in a trial comparing its lead product to a rival drug and questions arose over the role of its chief executive in a related report. 31 May 2017
Ireland-incorporated biotech firm Alkermes has named Craig Hopkinson to the posts of chief medical officer, and senior vice president of clinical development and medical affairs. 31 May 2017
Shares in US biotech firm Alexion Pharmaceuticals slumped nearly 10% today as investors were unsettled by a raft of management changes from new chief executive Ludwig Hantson. 24 May 2017
Actelion has detailed changes to its management team that will come into effect once the Swiss biotech firm becomes part of Johnson & Johnson. 16 May 2017
Japan’s Astellas Pharma has promoted Shontelle Dodson to senior vice president and head of medical affairs Americas, effective May 15, 2017. Ms Dodson previously served as vice president of medical excellence within the global medical affairs organization. 12 May 2017
German family-owned drugmaker Grünenthal has appointed Mark Fladrich to the position of chief commercial officer (CCO) responsible for the firm’s entire global commercial organization. 9 May 2017
Cambridge, UK-based monoclonal antibody specialist Kymab Group today announced the appointment of Dr Sonia Quaratino as its first chief medical officer. Dr Quaratino will manage the clinical development of the group's expanding therapeutic antibody portfolio. 9 May 2017
US biotech Seattle Genetics has agreed to terminate its license agreement with Immunomedics for cancer drug candidate sacituzumab govitecan (IMMU-132) and settle the related litigation. 8 May 2017
Paris, France-based GenSight Biologics has appointed Mohamed Genead, the former head of ophthalmology/retina gene therapy at Biogen, as the company’s new chief medical officer. 4 May 2017
Bayer hA appointed Bhavesh Ashar as senior vice president and head of oncology for the company's Pharmaceuticals Division in the USA, reporting to Carsten Brunn, head of Bayer Pharmaceuticals for the Americas region. 3 May 2017